



(12) Translation of
european patent specification

(11) NO/EP 2491045 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 513/04 (2006.01)
A61K 31/433 (2006.01)
A61P 25/08 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2016.05.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.12.23
(86)	European Application Nr.	10781818.9
(86)	European Filing Date	2010.10.21
(87)	The European Application's Publication Date	2012.08.29
(30)	Priority	2009.10.23, EP, 09173912
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	UCB Biopharma SPRL, 60, Allée de la Recherche, 1070 Brussels, BE-Belgia
(72)	Inventor	QUESNEL, Yannick, c/o UCB Pharma S.A., 60 allée de la Recherche, B-1070 Brussels, BE-Belgia TURET, Laurent, c/o UCB Pharma, S.A., 60, allée de la Recherche, B-1070 Bruxelles, BE-Belgia MERCIER, Joël, c/o UCB Pharma S.A., 60 allée de la Recherche, B-1070 Brussels, BE-Belgia
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES
(56)	References Cited:	WO-A1-2005/054188 WO-A2-01/62726 WO-A2-2006/128692 WO-A2-2006/128693

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. 2-okso-1-pyrrolidinylimidazotiadiazol-derivater i henhold til formel I, deres
 5 geometriske isomerer, enantiomerer, diastereomerer og blandinger, eller et farmasøytisk akseptabelt salt derav,



hvor

10 R^1 er et C_{1-4} alkyl inneholdende minst én halogensubstituent;
 R^2 er enten et halogen eller et C_{1-4} alkyl inneholdende minst én halogen-
 substituent;
 R^3 er et C_{1-4} alkyl inneholdende minst én hydroksy- eller alkoksylsubstituent,
 forbindelsene med formel (I) eventuelt er deuterert i hvilken som helst stilling.

15 2. Forbindelse ifølge krav 1, hvor R^1 er en 2,2-difluorpropyl-, 2-klor-2,2-difluoretyl-,
 en 2,2-difluoretyl-, en 2,2,2-trifluoretyl-, en 3,3,3-trifluorpropyl- eller en 2-fluoretyl-
 del.

20 3. Forbindelse ifølge krav 1 eller 2, hvor R^2 er enten en klor-, en difluormetyl- eller en
 trifluormetyl-del.

4. Forbindelse ifølge hvilket som helst av de foregående krav, hvor R^3 er enten en
 hydroksymetyl-, en metoksymetyl-, en [$(^2H_3)$ metyloksi]metyl-, en metoksy(2H_2)-
 25 metyl-, en (2,2,2-trifluoretoksy)metyl- eller en 2-metoksyetyl-del.

5. Forbindelse ifølge hvilket som helst av de foregående krav, hvor

30 R^1 er en 2,2-difluorpropyl-, 2-klor-2,2-difluoretyl-, en 2,2,2-trifluoretyl- eller en
 3,3,3-trifluorpropyl-del;
 R^2 er en klor-, en difluormetyl- eller en trifluormetyl-del;
 R^3 er en metoksymetyl-del.

6. Forbindelse ifølge hvilket som helst av de foregående krav som er valgt fra gruppen bestående av:

- 5 4-(2,2-difluorpropyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b]-
[1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
(+)-4-(2,2-difluorpropyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b]-
[1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
(-)-4-(2,2-difluorpropyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b]-
[1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
10 4-(2-klor-2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b]-
[1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on-trifluoracetat;
(4S)-4-(2-klor-2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo-
[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
(4R)-4-(2-klor-2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo-
15 [2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
4-(2-klor-2,2-difluoretyl)-1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo[2,1-
b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
(4R)-4-(2-klor-2,2-difluoretyl)-1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo-
[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
20 (4S)-4-(2-klor-2,2-difluoretyl)-1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo-
[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;
1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on;
(4R)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
25 metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on;
(4S)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on;
1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on;
30 1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;
(4S)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;
(4R)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl]-
35 metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;
(4S)-1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-
yl)metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;

4-(2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]-tiadiazol-5-yl)metyl}pyrrolidin-2-on;

(+)-4-(2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on, isomer A;

5 (-)-4-(2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on, isomer B;

4-(2-klor-2,2-difluoretyl)-1-{{6-(difluormetyl)-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

10 (-)-4-(2-klor-2,2-difluoretyl)-1-{{6-(difluormetyl)-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

(+)-4-(2-klor-2,2-difluoretyl)-1-{{6-(difluormetyl)-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

4-(2-klor-2,2-difluoretyl)-1-({6-klor-2-[(2,2,2-trifluoretoksy)metyl]imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

15 1-{{6-klor-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;

(-)-1-{{6-klor-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;

20 (+)-1-{{6-klor-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on;

1-{{6-klor-2-(metoksymetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(2-fluoretyl)pyrrolidin-2-on;

(4R)-1-{{2-(hydroksymetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on;

25 (4R)-4-(2-klor-2,2-difluoretyl)-1-{{2-{{²H₃}}metyloksy)metyl}-6-(trifluormetyl)-imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

(4R)-4-(2-klor-2,2-difluoretyl)-1-({2-[metoksy(²H₂)metyl]-6-(trifluormetyl)-imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

30 (4R)-4-(2-klor-2,2-difluoretyl)-1-{{2-(metoksymetyl)-6-(trifluormetyl)-imidazo[2,1-b][1,3,4]tiadiazol-5-yl}(2H₂)metyl}pyrrolidin-2-on

4-(2-klor-2,2-difluoretyl)-1-{{2-(2-metoksyetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}pyrrolidin-2-on;

1-{{2-(2-metoksyetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(2,2,2-trifluoretyl)pyrrolidin-2-on; og

35 1-{{2-(2-metoksyetyl)-6-(trifluormetyl)imidazo[2,1-b][1,3,4]tiadiazol-5-yl)metyl}-4-(3,3,3-trifluorpropyl)pyrrolidin-2-on.

7. Forbindelse ifølge hvilket som helst av kravene 1 til 6, for anvendelse som et medikament.

5 8. Et farmasøytisk preparat omfattende en effektiv mengde av en forbindelse ifølge krav 1 til 6, i kombinasjon med et farmasøytisk akseptabelt fortynningsmiddel eller bærer.

9. Forbindelse ifølge hvilket som helst av kravene 1 til 6, for anvendelse ved behandling av pasienter med refraktær epilepsi.